Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2023 Mar;31(3):703-715.
doi: 10.1002/oby.23673. Epub 2023 Jan 18.

Two-year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5

Sean Wharton  1 , Rachel L Batterham  2   3   4 , Meena Bhatta  5 , Silvio Buscemi  6   7 , Louise N Christensen  5 , Juan P Frias  8 , Esteban Jódar  9   10 , Kristian Kandler  5 , Georgia Rigas  11 , Thomas A Wadden  12 , W Timothy Garvey  13
Affiliations
Randomized Controlled Trial

Two-year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5

Sean Wharton et al. Obesity (Silver Spring). 2023 Mar.

Abstract

Objective: This study evaluated the effect of once-weekly semaglutide 2.4 mg on 2-year control of eating.

Methods: In STEP 5, adults with overweight/obesity were randomized 1:1 to semaglutide 2.4 mg or placebo, plus lifestyle modification, for 104 weeks. A 19-item Control of Eating Questionnaire was administered at weeks 0, 20, 52, and 104 in a subgroup of participants. P values were not controlled for multiplicity.

Results: In participants completing the Control of Eating Questionnaire (semaglutide, n = 88; placebo, n = 86), mean body weight changes were -14.8% (semaglutide) and -2.4% (placebo). Scores significantly improved with semaglutide versus placebo for Craving Control and Craving for Savory domains at weeks 20, 52, and 104 (p < 0.01); for Positive Mood and Craving for Sweet domains at weeks 20 and 52 (p < 0.05); and for hunger and fullness at week 20 (p < 0.001). Improvements in craving domain scores were positively correlated with reductions in body weight from baseline to week 104 with semaglutide. At 104 weeks, scores for desire to eat salty and spicy food, cravings for dairy and starchy foods, difficulty in resisting cravings, and control of eating were significantly reduced with semaglutide versus placebo (all p < 0.05).

Conclusions: In adults with overweight/obesity, semaglutide 2.4 mg improved short- and longer-term control of eating associated with substantial weight loss.

PubMed Disclaimer

References

REFERENCES

    1. Garvey WT, Mechanick JI, Brett EM, et al. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22(suppl 3):1-203.
    1. Yumuk V, Tsigos C, Fried M, et al. European guidelines for obesity management in adults. Obes Facts. 2015;8:402-424.
    1. Sumithran P, Prendergast LA, Delbridge E, et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011;365:1597-1604.
    1. Wegovy. Prescribing information. Novo Nordisk; 2021. Updated June 2021. Accessed November 1, 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215256s000lbl.pdf.
    1. Gabery S, Salinas CG, Paulsen SJ, et al. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight. 2020;5:e133429. doi:10.1172/jci.insight.133429

Publication types

LinkOut - more resources